¼¿ï¼º¸ðº´¿ø Áö¹æ°£¿¬±¸È¸ 2019 ½ÉÆ÷Áö¾ö : 2019-07-20±³À°ÀÏÀÚ : 2019-07-20
±³À°Àå¼Ò : ¼¿ï¼º¸ðº´¿ø ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
Áö¹æ°£¿¬±¸È¸ 2019 ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : À¯ÁöÀÎ
¿¬¶ôó : 02-714-9072
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 09:40~10:10 Epidemiology of NAFLD in Diabetes ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 10:10~10:40 Clinical Features & natural course of NAFLD ÀÌ¿ø¿µ(¼º±Õ°üÀÇ´ë)
Åä·Ð 07-20 ¼¿ï¼º¸ðº´¿ø 10:40~10:50 Q&A ()
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 10:50~11:10 Glucose and fat metabolism of liver in healthy person ¹Ú±Ù±Ô(°æºÏÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 11:10~11:50 Molecular Mechanisms in the Development and Progression of NAFLD ÀÌ´ëÈ£(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 11:50~12:10 Genes & NAFLD in T2D ±è¿ø(¼¿ï´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 13:10~13:50 pathology ä½Â¿Ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 13:50~14:30 New Liver imagingL US, CT, MR-PDFF, MRE À̽¼ö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 14:30~14:45 transient elastography ±è½Â¾÷(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 14:45~15:05 Physical examination & blood testing for liver function evaluation and diagnosis ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë)
Åä·Ð 07-20 ¼¿ï¼º¸ðº´¿ø 15:05~15:15 Q&A ()
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 15:30~16:00 Life Style modification À̺´¿Ï(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 16:00~16:40 Non-Hypoglycemic & Hypoglycemic Agents ¹Úö¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07-20 ¼¿ï¼º¸ðº´¿ø 16:40~17:00 Bariatric Surgery ±è¿ëÁø(¼øõÇâ´ëÇÐ)
Åä·Ð 07-20 ¼¿ï¼º¸ðº´¿ø 17:00~17:10 Q&A ()